Journal de la Faculté de Médecine d'Oran (Apr 2022)

Conformational radiotherapy of no metastatic prostate cancer: Experience of the radiation therapy department of EHS Oncology Emir Abdelkader of Oran

  • Lotfi TALEB,
  • Karima CHENNI,
  • Ismail Zergoug,
  • Abdelbaki Boukerche,
  • Ahmed Fethi Dali-Youcef

Journal volume & issue
Vol. 1, no. 02

Abstract

Read online

Introduction - Over the last decades, prostate cancer has become a public health condition, due to its frequency and severity. The conformational radiotherapy constituted today the standard technique in the irradiation of non-metastatic prostate cancers due to the benefit in terms of tolerance and disease control compared to conventional 2D radiotherapy. Our study has been conducted at the Radiation Therapy Department of EHS Oncology Emir Abdelkader of Oran, the only service equipped with a 3D conformal radiotherapy technical platform in western Algeria. It has for objective to study the survival without biochemical relapse and the overall survival of patients with non-metastatic prostate cancer treated during the period of June 2010 to December 2014. Patients and methods - We made a descriptive study type of prospective. During the period of the study, 90 patients with non-metastatic prostate cancer had been treated with conformal radiotherapy. Results - The mean age of our series was 66.3 years. Prostate cancer was diagnosed at a locally advanced and / or localized high-risk stage according to the AMICO classification in 80% of cases. Radiotherapy was exclusive in 80 patients, immediate postoperative in five patients and catch up in five cases. Hormone therapy was associated with radiotherapy in the majority of patients, 94.4% of cases. With a median follow-up of 31 months; the probability of survival without biochemical relapses is 64% , while overall survival is estimated at 93.7%. Conclusion - In our series, prostate cancer is diagnosed at an advanced stage of the disease in a relatively young population. Conformal radiotherapy represents a real breakthrough in the treatment of prostate cancer, both in terms of tolerance and effectiveness. Longer follow-up and more patient recruitment is needed to validate the results.

Keywords